168 related articles for article (PubMed ID: 31903932)
1. [Developability assessment].
Dumas J; Huille S; Prades C
Med Sci (Paris); 2019 Dec; 35(12):1163-1170. PubMed ID: 31903932
[TBL] [Abstract][Full Text] [Related]
2. [Developability assessment with case studies highlighting the decision taking].
Dumas J; Sévérac A; Lemoine C; Huille S; Rak A; Prades C
Med Sci (Paris); 2019 Dec; 35(12):1171-1174. PubMed ID: 31903933
[TBL] [Abstract][Full Text] [Related]
3. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
4. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
5. Nanobodies.
Gibbs WW
Sci Am; 2005 Aug; 293(2):78-83. PubMed ID: 16053141
[No Abstract] [Full Text] [Related]
6. Biosimilars: An Approach to some Current Worldwide Regulation Frameworks.
Esteban E; Bustos RH; García JC; Jáuregui E
Curr Clin Pharmacol; 2019; 14(1):16-40. PubMed ID: 30360724
[TBL] [Abstract][Full Text] [Related]
7. Antibody fragments for controlled delivery of therapeutic agents.
Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
[No Abstract] [Full Text] [Related]
8. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.
Farhat F; Torres A; Park W; de Lima Lopes G; Mudad R; Ikpeazu C; Abi Aad S
Oncologist; 2018 Mar; 23(3):346-352. PubMed ID: 29284760
[TBL] [Abstract][Full Text] [Related]
9. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.
Beck A; Reichert JM
MAbs; 2013; 5(5):621-3. PubMed ID: 23924791
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
Calvo B; Zuñiga L
Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
[TBL] [Abstract][Full Text] [Related]
11. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
Ishii-Watabe A; Kuwabara T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
Golay J; Introna M
Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
[TBL] [Abstract][Full Text] [Related]
13. The advent of biosimilars: challenges and risks.
Müller R; Renner C; Gabay C; Cassata G; Lohri A; Hasler P
Swiss Med Wkly; 2014; 144():w13980. PubMed ID: 24984255
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar infliximab: an expert view.
Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
[TBL] [Abstract][Full Text] [Related]
15. First biosimilar drug set to enter US market.
Ledford H
Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
[No Abstract] [Full Text] [Related]
16. Antibody Engineering & Design 2010. 24-25 February 2010, Frankfurt, Germany.
Beck A
IDrugs; 2010 May; 13(5):295-9. PubMed ID: 20432182
[TBL] [Abstract][Full Text] [Related]
17. [MI-mAbs, pre-industrial demonstrator supported by PIA for the early validation of therapeutic targets using monoclonal antibodies].
Romagné F
Med Sci (Paris); 2019 Dec; 35(12):1202-1203. PubMed ID: 31903940
[No Abstract] [Full Text] [Related]
18. A Streamlined Bioanalytical Approach to Select a Compatible Primary Container System Early in Drug Development: A Toolbox for the Biopharmaceutical Industry.
Singh R; Waxman L
J Pharm Sci; 2020 Jan; 109(1):206-210. PubMed ID: 31545968
[TBL] [Abstract][Full Text] [Related]
19. Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy.
De Santis R
MAbs; 2020; 12(1):1725346. PubMed ID: 32054397
[TBL] [Abstract][Full Text] [Related]
20. The US Biosimilar Market: Stunted Growth and Possible Reforms.
Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS
Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
